Vice President Joe Biden, Dr. Oliver Press, and Senator Patty Murray at Fred Hutch before attending a roundtable discussion on cancer research, March 21, 2016. (Official White House Photo by David Lienemann)
Press lab group at Fred Hutchinson Cancer Research Center. Taken March 30, 2016.
Oliver Press and Nancy Ottman Press received the Lymphoma Research Foundation Distinguished Service Award in New York on September 27, 2017
Oliver Press posthumously received the John Ultmann Award for Contributions to Lymphoma Research in New York on October 28, 2017. Watch the video of the award ceremony with Morton Coleman, MD; David Maloney, MD PhD; Ruth Ultmann; Michael F. Press, MD, PhD; and Nancy Ottman Press.
Oliver Press posthumously received the Leukemia & Lymphoma Society, Washington/Alaska Chapter, Remembered Hero Award, 2018.
Oliver Press posthumously received the Leukemia & Lymphoma Society's Robert de Villiers Spiral of Life Award (LLS's highest award), 2018.
Stanford University, "Dedicated Researcher, Physician and Mentor"
American Association for Cancer Research, "In Memoriam: Oliver W. Press, MD, PhD"
American Society for Clinical Oncology, "Leading Lymphoma Clinician, Researcher, and Mentor, Oliver "Ollie" Press, MD, Phd, Dies at 65," and "ASCO Remembers Dr. Oliver Press"
Clinical Advances in Hematology & Oncology, "In Memory of Oliver Press, MD, PhD"
University of Washington Department of Medicine, "Remembering Ollie Press"
The Hematologist, "Oliver W. Press, MD, PhD (1952-2017)"
Lymphoma Research Foundation, "Passing of Dr. Oliver Press"
The Press Lab at the Fred Hutchinson Cancer Research Center is devoted to the investigation of novel treatments for hematologic malignancies including non-Hodgkin's lymphoma, leukemia, and myeloma. We conduct basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, we are continuing our successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and have trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.